Evidence map›Paper›PMID 35630948›Full record

ArticleNanomaterials (Basel, Switzerland)2022

A Novel Cu

Liliya Sh Altynbaeva, Murat Barsbay, Nurgulim A Aimanova, Zhanar Ye Jakupova, Dinara T Nurpeisova, Maxim V Zdorovets, Anastassiya A Mashentseva

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Correction: Altynbaeva et al. A Novel CuNanomaterials (Basel, Switzerland) · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. A Review on CuMolecules (Basel, Switzerland) · 2023
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Liliya Sh AltynbaevaThe Institute of Nuclear Physics of the Republic of Kazakhstan, Almaty 050032, Kazakhstan.
Murat BarsbayDepartment of Chemistry, Hacettepe University, 06800 Ankara, Turkey.ORCID 0000-0003-0788-4446
Nurgulim A AimanovaThe Institute of Nuclear Physics of the Republic of Kazakhstan, Almaty 050032, Kazakhstan.ORCID 0000-0002-9150-5877
Zhanar Ye JakupovaDepartment of Chemistry, L.N. Gumilyov Eurasian National University, Nur-Sultan 010008, Kazakhstan.
Dinara T NurpeisovaDepartment of Chemistry, L.N. Gumilyov Eurasian National University, Nur-Sultan 010008, Kazakhstan.
Maxim V ZdorovetsThe Institute of Nuclear Physics of the Republic of Kazakhstan, Almaty 050032, Kazakhstan.ORCID 0000-0003-2992-1375
Anastassiya A MashentsevaThe Institute of Nuclear Physics of the Republic of Kazakhstan, Almaty 050032, Kazakhstan.ORCID 0000-0003-4393-5845
L. N. Gumilyov Eurasian National University · KZHacettepe University · TRNational Nuclear Center of the Republic of Kazakhstan · KZ

Funding

Ministry of Education and Science of the Republic of Kazakhstan AP08855527
6 · The paper itself

Abstract

The extremely high levels of water pollution caused by various industrial activities represent one of the most important environmental problems. Efficient techniques and advanced materials have been extensively developed for the removal of highly toxic organic pollutants, including pesticides. This study investigated the photocatalytic degradation of the fungicide carbendazim (Czm) using composite track-etched membranes (TeMs) in an aqueous solution. Copper(I) oxide (Cu

Indexed as

carbendazim removalcomposite track-etched membranescopper(I) oxideelectroless template depositionphotocatalytic degradation of pesticidewastewater pollutantzinc oxide nanostructures

Identifiers

PMID35630948
PMCPMC9144458
OpenAlexW4280511131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.